Where to from here? I hope they quickly recruit another 7 patients and complete this trial. Coupled the data and the IDMC recommendation that it is unethical to continue to deny patients access to Her-Vaxx, IMU would probably get fast-track permission from FDA.
And with that, Roche rocks up and plonk $5bn for the exclusive rights to market Her-Vaxx on a 50/50 profit sharing deal. Or they can buy Her-Vaxx outright for at least $40bn. This can potentially happen in 2021.
IMU Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)